In the latest move by Anthem Inc., the company announced earlier this week that it plans to acquire Aspire Health, the nation’s largest non-hospice advanced care provider.
In the latest move by Anthem Inc., the company announced earlier this week that it plans to acquire Aspire Health, the nation’s largest non-hospice advanced care provider.
“Aspire Health shares our perspective on the increasingly important role of integrated care and has built a unique model that provides palliative care and support for support services for patients and their families,” said Gail K. Boudreaux, president and CEO of Anthem, in a statement.
Aspire was founded in 2013 by former US Senator William Frist, MD, and Brad Smith, who serves as the CEO. The company uses proprietary predictive clinical technology and claims-based patient algorithms to identify patients that have a serious illness who may benefit from added support. Once patients are identified, Aspire establishes a comprehensive integrated care team to address symptom management, coordinated care, and advanced care planning.
“As part of Anthem, we believe we will be able to further scale our model and positively impact the lives of even more consumers and families, making home-based advanced illness care available to patients who need it,” said Smith in a statement.
CMS has previously estimated that the average rate of national health spending will grow 5.5% per year from 2017 to 2026, reaching nearly $5.7 trillion. According to a study published last year in Health Affairs, end-of-life care is among the most expensive healthcare costs, reaching a mean of $80,000 per capita in the last 12 months of life.
In the past, Anthem has attempt to curtail healthcare costs in controversial ways. Last year, it announced that emergency department (ED) visits would no longer be covered by the insurer in cases where it deemed the visit unnecessary. It amended this policy in February 2018, stating that exceptions would be made for patients sent to an ED by a provider, those from out of state who present to the ED on the weekend, and those who end up receiving certain types of medical care such as surgery, intravenous (IV) fluids, or a magnetic resonance imaging (MRI) or computed tomography (CT) scan.
The acquisition is expected to be finalized in the third quarter of 2018, and the financial terms of the acquisition were not disclosed.
Eye on Pharma: Bevacizumab Update; Samsung Bioepis, J&J Settlement; Another EU Trastuzumab
December 6th 2023Outlook Therapeutics provides an update on the development of its bevacizumab candidate for age-related macular degeneration; Samsung Bioepis settles with Johnson & Johnson (J&J) over its ustekinumab biosimilar candidate; and the European Union gains another trastuzumab biosimilar.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
CVS Caremark Switches Up Biosimilar Coverage in 2024
November 27th 2023As new biosimilars are added to CVS Caremark’s standard formulary, others are removed. One notable change is with the Humira biosimilars: the pharmacy benefit manager has removed Amjevita in favor of Hyrimoz and an unbranded biosimilar.
Biosimilars Business Roundup For August 2023—Podcast Edition
September 5th 2023On this episode, we’re giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.
AMCP Nexus: Panelists Share Current Scope of Biosimilar Industry
October 26th 2023Panelists at the Academy of Managed Care Pharmacy (AMCP) Nexus meeting chronicled the current state of the US biosimilar market, including current policies impacting the market, recent regulatory decisions, and the developing arguments around requirements for clinical efficacy studies.